

BACIL PHARMA LIMITED

Regd. Off: 71, LAXMI BUILDING 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI: 400001.
Email: bacilpha@yahoo.com CIN: L24200MH1987PLC043427, Tel: 22618452/22661541, Tel/Fax: 22618327

13th February, 2021

To
The Bombay Stock Exchange Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Dear Sir/ Madam,

BSE SCRIP CODE: 524516

Name: Bacil Pharma Limited

Sub: Outcome of Board Meeting of the Company

This is to inform the exchange that the meeting of Board of Directors of the M/s. Bacil Pharma Limited has been duly convened on Saturday, 13th day of February, 2021 through Video Conferencing. The Board transacted following items:

- Approved and adopted the un-audited Financial Results of the Company for the Quarter and nine-months ended 31st December, 2020.
- Approved Limited Review Report for the Quarter ended 31st December, 2020.
- Other Items with the permission of Board.

Please note that the Meeting of the Board of Directors commenced at 06.00 P.M. and concluded at 06.15 P.M

Kindly take the note of the same and update on your records.

Thanking You,

For Bacil Pharma Limited.



Prakash Shah
Director
DIN: 01136800



BACIL PHARMA LIMITED

CIN:L24200MH1987PLC043427

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2020

(Amount in Lacs)

Sr. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	-	-	-	-	-	-
	Other income	3.51	2.40	1.97	7.58	12.45	14.28
	Total revenue	3.51	2.40	1.97	7.58	12.45	14.28
2	Expenses						
	Employee benefits expense	1.96	0.71	2.71	3.18	7.13	9.37
	Depreciation and amortization expense	0.12	0.12	0.21	0.37	0.62	0.82
	Other expenses	4.67	2.29	23.89	8.60	34.00	35.64
	Total expenses	6.75	3.12	26.81	12.15	41.74	45.84
3	Profit/(Loss) from exceptional item before tax	(3.24)	(0.71)	(24.84)	(4.57)	(29.30)	(31.56)
	Exceptional Item	-	-	-	-	-	-
4	Profit / (Loss) from ordinary activities before tax	(3.24)	(0.71)	(24.84)	(4.57)	(29.30)	(31.56)
5	Tax expense:						
	(1) Current tax	-	-	-	-	-	-
	(2) Earlier year's Tax	-	-	-	-	-	-
	(3) Deferred tax	0.01	0.01	(0.03)	0.03	(0.01)	0.04
6	Profit/(Loss) from ordinary activities after tax	(3.23)	(0.70)	(24.87)	(4.54)	(29.31)	(31.52)
7	Other Comprehensive Income (OCI)						
	Item that will not be reclassified to profit or loss						
	Gain/(Loss) on recognised on fair valuation of Financial Assets	18.41	1.55	14.10	35.88	(8.51)	(28.47)
	Income tax relating to these items	(4.79)	(0.40)	(3.67)	(9.51)	2.21	7.59
	Total Other Comprehensive Income (OCI)	13.62	1.14	10.43	26.37	(6.29)	(20.89)
	Profit/(Loss) for the Period	10.39	0.44	(14.44)	21.83	(35.60)	(52.41)
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	589.00	589.00	589.00	589.00	589.00	589.00
8	Earning Per Share (EPS) (Not annualised)						
	(1) Basic	(0.05)	(0.01)	(0.42)	(0.08)	(0.50)	(0.54)
	(2) Diluted	(0.05)	(0.01)	(0.42)	(0.08)	(0.50)	(0.54)

Notes:

- The above Financial Results were reviewed and recommended by the audit committee and approved by the Board of Directors of the Company at their Meeting held on Saturday, 13th February, 2021. The Statutory auditor have expressed an unmodified opinion.
- The statutory Auditors of the company have carried out the limited review.
- The Company has single business segment therefore in the context of Ind AS 108, disclosure of segment information is not applicable.
- An amount of Rs. 250 Lacs has been received earlier as advance on account of sale consideration of Leasehold Land, Building, Plant & Machinery and Other Equipments on "as is where is basis" situated at Lote Parshuram, MIDC. The conveyance of the same is pending due to adjustments on account of adjudication by the stamp authority. Due to COVID-19, there was a nationwide lockdown, and the company could not complete the sale transaction with the buyer. The Management believes that the same will be completed in a short time during the F.Y. 2020-21. The accounting impact will be given once the transaction is completed.
- The above Financial Results which are published in accordance with the regulation 33 of the Securities and Exchange Board of India (Listing Obligation & Disclosure Requirements) Regulations, 2015

For BACIL PHARMA LIMITED


Prakash Shah
 Director
 DIN: 01136800
 Place: Mumbai
 Date: 13th February, 2021





Laxmikant Kabra & Co.

Chartered Accountants

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors
Bacil Pharma Limited

1. We have reviewed the accompanying statement of unaudited financial results of Bacil Pharma Limited (the "Company") for the quarter and nine months ended December 31, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules Issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Laxmikant Kabra & Co.
Chartered Accountants
Firm Reg. No.: 117183W

L.K. Kabra

CA Laxmikant Kabra
Partner
Membership No.: 101839
UDIN: 21101839AAAADK9547



Place: Thane
Date: 13th February 2021